Myocardial Ischemia and Infarction tration of edaravone at 10 min before reperfusion and immediately after reperfusion had a cardioprotective effect against ischemia-reperfusion injury, but the treatment with edaravone at 5 min after reperfusion did not show this protective effect.
Background: Bone marrow-derived mononuclear cells (BM-MNCs) can give rise to endothelial progenitor cells and localized transplantation of BM-MNCs in ischemic myocardium may augment neovascularization. However, not much is known of the arrhythmogenic potential of BM-MNCs after intramyocardial transplantation. Objective: Evaluate the threshold for ventricular arrhythmia induction with conventional electrophysiologic study (EPS) with programmed stimulation in swine with chronic myocardial ischemia treated with autologous BM-MNCs. Methods: Adult Yucatan swine underwent left circumflex (LCX) ameroid implantation. At 4 weeks, animals were randomized to receive either BM-MNCs (n=8) or DMEM culture medium as control (n=8). Bone marrow (30-50ml) was aspirated from sternum and if necessary, iliac crest. Mononuclear cells were isolated using density gradient centrifugation. Catheter-based (Boston Scientific Stiletto TM ) intramyocardial injections were performed with combined fluoroscopic and intracardiac echocardiography (ICE) guidance. The treatment group received total of 1 x 10 8 BM-MNCs at 10 sites, 5 in ischemic (LCX), and 5 in non-ischemic (LAD) region. Four weeks after cell treatment, global wall motion score index (GWMSI) was evaluated by dobutamine stress echocardiography. Subsequently, electrophysiologic study was performed with right ventricle stimulation at apex and outflow tract, using a basic cycle length of 500 and 400msec and 1-3 extrastimuli. Results: No difference was found in total number of cases with inducible arrhythmias in BM-MNC and control groups: 3 out of 8 animals (38%) in BM-MNC group (2 polymorphic VT and 1 VF) and 3 out of 8 animals (38%) in control group (1 monomorphic VT and 2 VF). There was also no difference in global wall motion (GWMSI=1.03 in BM-MNCs; 1.17 in sham, p=0.38) and there was no correlation between GWMSI and ventricular arrhythmia induction (1.29 for induced pigs; 1.01 for non-induced, p=0.09). Conclusion: Transplantation of autologous BM-MNCs into ischemic myocardium did not alter the threshold for ventricular arrhythmia. Left ventricular dysfunction was not related to arrhythmia inducibility.
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Monocyte Monocyte chemoattractant protein 1 (MCP-1) stimulates invasion of monocytes into ischemic tissue with concomitant adhesion to endothelial cells. This process has been shown to be involved in the induction of arteriogenesis, i.e., the development of functional arterioles resulting in improvement of perfusion in contrast to angiogenesis without changes in blood flow. The effects of MCP-1 on angiogenesis and arteriogenesis and changes of left ventricular function were tested in infarcted rat hearts. Anesthesized rats were subjected to open-chest ligation of the left coronary artery with subsequent myocardial infarction. After six weeks, animals were randomized to receive either MCP-1 (3µl in 0.15ml NaCl, group1, n=9) or saline (0.15ml, group 2, n=9), which was injected after thoracotomy into the myocardium at the infarct border zones. Transthoracic echocardiography was performed for assessment of left ventricular dimensions and cardiac function (ejection fraction, EF) at baseline, six weeks after myocardial infarction, and four weeks after MCP-1 or saline injection, by use of a 12 MHz pediatric transducer. For microscopic analysis, myocardial tissue was stained by Elastica-van-Giesson and von-Willebrand factor for blood vessels and endothelial cells, respectively. In a subset of animals, hearts were excised 24 hours after MCP-1 (n=4) or saline (n=4) administration for assessment of monocyte infiltration by staining of the CD 31 antigen. EF decreased from 60±3% to 25±5% in group 1 (p<0.005) and from 58±2% to 26±4% in group 2 (p<0.005) after coronary occlusion, without further changes four weeks after treatment (EF 26±3% in group1, EF 25±5% in group 2). At the injection site, 391±10 endothelial cells were found in group 1 versus 285±14 in group 2 (p<0.005). Monocyte infiltration was shown in MCP-1 treated animals but not in saline treated animals. There were 19±2 arteriolar structures in group 1 versus 16±1 in group 2, p>0.05. A single intramyocardial injection of MCP-1 into the infarct border zone induced neo-angiogenesis and monocyte infiltration. MCP-1 injection did not result in arteriogenesis or functional improvement of chronically infarcted myocardium in this experimental rat model. The MVP ® System is a magnetic anastomotic coupling system that allows quick and reliable connections between a coronary artery and an autologous bypass graft. One magnetic clip set (3 miniature magnets) forms a port in the target vessel while a matching magnetic clip set forms an identical port of opposite polarity in the terminal portion of the graft vessel. When brought together, the two ports form the anastomosis. This multi-center European registry represents the first MVP ® clinical experience for anastomosis between the left anterior descending artery (LAD) and the left internal mammary artery (LIMA). We report the 6-month angiographic follow-up (FU). Methods: 48 consecutive patients underwent coronary bypass surgery, including LIMA to the LAD using the MVP ® device. Angiographic FU was performed and the results compared to the graft occlusion rate for the control arm of the GABI trial (German Angioplasty vs. Bypass Surgery Investigation), which was 13% at six months of FU. Results: Angiographic results at FU are shown in the Table. Conclusions: In this European multi-center registry, the MVP ® anastomosis device and target vessel patency was 93.8% and 91.7% respectively for anastomosis between the LIMA and LAD at 6 months of FU. The device and target vessel occlusion rates of 6.2% and 8.3%, were equivalent to the historic control obtained in the GABI trial (13% occlusion). In addition, there was no evidence of thrombus, ectasia, aneurysmal dilatation, intimal flap or ulceration in any of the cases at FU. Objective: Interventions that target the cardiac conduction system such as AICD placement and biventricular pacing improve symptoms and survival in patients with congestive heart failure.However, the role of the conduction system in outcome after surgical ventricular reconstruction, the excision of dyskinetic and akinetic segments of myocardium, remains undefined. We reviewed our experience with left ventricular reconstruction (LVR) in patients with ischemic cardiomyopathy to determine the effect of preoperative conduction abnormalities on outcome after surgery. Methods: LVR was performed in 223 pts (80% male, mean age 62± 10 yrs, 66% NYHA Class III/IV) between 1/97 and 8/02. Mean pre-operative EF was 26 ± 9%. QRS duration was 122 ± 32msec and an AICD was present in 15%. Time related outcomes considered were 1) survival, 2) freedom from composite event (transplant, return of NYHA class IV, and LVAD), and 3) readmission for heart failure. Mean follow-up is 1.5 ± 1.1 yrs. Results: Survival at 30 days, 1yr, and 3 yrs was 98%, 92%, and 86% respectively. Patients who had an AICD preoperatively had a higher early mortality (<2 years) (95% vs 77% 2 yrs, p=0.0001). Freedom from composite event was 97%, 89%, and 83%. Patients who had a prolonged preoperative QRS were more likely to suffer a composite event (p=0.0002). Freedom from readmission for heart failure was 99%, 80%, and 61% at 30 days, 1 yr, and 3 yrs. Patients with a prolonged preoperative QRS had more frequent rehospitalizations (p=0.006). Conclusion: Surgical left ventricular reconstruction in heart failure patients with ischemic cardiomyopathy yields an encouraging medium term survival and freedom from hospitalization for heart failure. Preoperative predisposition to lethal ventricular arrhythmia requiring an AICD was a strong predictor of mortality. This deserves closer examination. Left ventricular dysynchrony (prolonged QRS) was a strong predictor of residual or recurrent heart failure and further underscores the importance of ongoing investigations of cardiac resynchronization therapy as an adjunctive treatment to surgery for heart failure in this group of at risk patients. 
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